Mydecine Innovations Group Inc. announced Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale have recently resigned as directors of the Company. The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency. Mr. Michaels will continue to serve as Chief Operating Officer for the organization.

As a result of the resignations, the Company is currently searching for candidates with a background in drug development to fill two board positions. Josh Bartch, Rob Roscow, and Todd Heinzl have the best interest of the company's stockholders and will continue to serve on the board for the foreseeable future.